{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:13:09Z","timestamp":1786363989083,"version":"build-2736575974"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious\n                    health and social consequences. However, few licensed and successful\n                    pharmacotherapies exist for heterogeneous and complex disorders such as AUD, and\n                    these are poorly utilized. Preclinical and clinical findings suggest that the\n                    glucagon-like peptide-1 (GLP-1) system, a gut-brain peptide, is involved in the\n                    neurobiology of addictive behaviors. Additionally, the GLP-1 receptor (GLP-1R)\n                    has become a promising target for the treatment of AUD. Semaglutide, a novel\n                    GLP-1R agonist, has received clinical approval to treat type 2 diabetes in both\n                    subcutaneous and oral dosage forms. Studies have shown that it significantly\n                    reduces alcohol consumption and relapse of alcohol addiction in rats, suggesting\n                    its potential effectiveness for treating alcohol abuse in humans, particularly\n                    in overweight patients with AUDs. However, the use of semaglutide is associated\n                    with potential risks, such as gallbladder disease and clinical complications\n                    associated with delayed gastric emptying. This review evaluates the safety of\n                    semaglutide to inform its wider clinical application. Further extensive and\n                    in-depth studies on semaglutide are needed to reveal additional valuable\n                    clinical benefits.<\/jats:p>","DOI":"10.1055\/a-2550-6470","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T19:08:21Z","timestamp":1744657701000},"page":"255-262","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide\n                    in Alcohol Use Disorder"],"prefix":"10.1055","volume":"58","author":[{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering, Changchun University of Technology,\n                    Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering, Changchun University of Technology,\n                    Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering, Changchun University of Technology,\n                    Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Li","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering, Changchun University of Technology,\n                    Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Qin","sequence":"additional","affiliation":[{"name":"The Third Bethune Hospital of Jilin University, Changchun,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195\n                    countries and territories, 1990\u20132016: A systematic analysis for the Global\n                    Burden of Disease Study 2016","volume":"5","author":"L Degenhardt","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref2","volume-title":"Global status report on alcohol and health 2018","author":"World Health Organization","year":"2018"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: Results from the National\n                    Epidemiologic Survey on Alcohol and Related Conditions III","volume":"72","author":"B F Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"M K Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"G F Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"A F Carvalho","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical\n                    evidence","volume":"136","author":"E Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013\n                    state-of-the-art","volume":"46","author":"M A Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"JP H Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: A review of the first oral glucagon-like peptide 1 receptor\n                    agonist","volume":"22","author":"J D Bucheit","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol\n                    drinking and modulates central GABA neurotransmission","volume":"8","author":"V Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female\n                    rats","volume":"93","author":"C Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2478\/jvetres-2018-0033","article-title":"GLP-1 Localisation and proglucagon gene expression in healthy and diabetic mouse\n                    ileum","volume":"62","author":"S K Ta\u015f\u00e7\u0131","year":"2018","journal-title":"J Vet Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger\n                    RNAs in the rat central nervous system","volume":"403","author":"I Merchenthaler","year":"1999","journal-title":"J Comp Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the\n                    ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"A L Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/db09-0063","article-title":"Glucagon-like peptide-1 protects \u03b2-cells against apoptosis by increasing the\n                    activity of an Igf-2\/Igf-1 receptor autocrine loop","volume":"58","author":"M Cornu","year":"2009","journal-title":"Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2337\/db16-1009","article-title":"Glucagon-like peptide 1 protects pancreatic \u03b2-cells from death by increasing\n                    autophagic flux and restoring lysosomal function","volume":"66","author":"F P Zummo","year":"2017","journal-title":"Diabetes"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.physbeh.2015.06.001","article-title":"Vagal mediation of GLP-1\u2019s effects on food intake and glycemia","volume":"152","author":"J-P Krieger","year":"2015","journal-title":"Physiol Behav"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.physbeh.2013.03.027","article-title":"Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy\n                    expenditure in rats after Roux-en-Y gastric bypass","volume":"121","author":"K Abegg","year":"2013","journal-title":"Physiol Behav"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"110303","DOI":"10.1016\/j.pnpbp.2021.110303","article-title":"The therapeutic potential of GLP-1 analogues for stress-related eating and role\n                    of GLP-1 in stress, emotion and mood: A review","volume":"110","author":"E Guerrero-Hreins","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2005.05.010","article-title":"Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors","volume":"1751","author":"D Hu","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1063033","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions\n                    based on findings from preclinical and clinical studies","volume":"14","author":"E Jerlhag","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with\n                    type 2 diabetes mellitus","volume":"62","author":"O G Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties\n                    suitable for once daily administration","volume":"43","author":"L B Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.09.2479","article-title":"Clinical implications of exenatide as a twice-daily or once-weekly therapy for\n                    type 2 diabetes","author":"V R Aroda","year":"2011","journal-title":"Postgrad Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.mce.2015.07.003","article-title":"Emerging opportunities for the treatment of metabolic diseases: Glucagon-like\n                    peptide-1 based multi-agonists","volume":"418","author":"B Finan","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1463-1326.2011.01365.x","article-title":"LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a\n                    dose-dependent effect on insulin secretion in healthy subjects","volume":"13","author":"P Barrington","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a\n                    long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"M A Bush","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"108904","DOI":"10.1016\/j.diabres.2021.108904","article-title":"Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes:\n                    A network meta-analysis","volume":"177","author":"L Xia","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"A Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are\n                    rapidly degraded from the NH2-terminus in type II diabetic patients and in\n                    healthy subjects","volume":"44","author":"C F Deacon","year":"1995","journal-title":"Diabetes"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"L B Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular\n                    benefits for management of type 2 diabetes","volume":"23","author":"M K Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue\n                    semaglutide","volume":"58","author":"J Lau","year":"2015","journal-title":"J Med Chem"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40268-021-00341-8","article-title":"A review on the efficacy and safety of oral semaglutide","volume":"21","author":"S Niman","year":"2021","journal-title":"Drugs RD"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1037\/h0058775","article-title":"Positive reinforcement produced by electrical stimulation of septal area and\n                    other regions of rat brain","volume":"47","author":"J Olds","year":"1954","journal-title":"J Comp Physiol Psychol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0006-3223(00)01038-6","article-title":"Amphetamine-induced dopamine release in human ventral striatum correlates with\n                    euphoria","volume":"49","author":"W C Drevets","year":"2001","journal-title":"Biol Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"599646","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol\n                    intake in male wistar rats","volume":"14","author":"V N Marty","year":"2020","journal-title":"Front Neurosci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with\n                    obesity","volume":"13","author":"F Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on\n                    alcohol consumption in alcohol-preferring male vervet monkeys","author":"A Fink-Jensen","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel\n                    oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects\n                    with type 2 diabetes","volume":"58","author":"C Granhall","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: A systematic review and\n                    meta-analysis","volume":"20","author":"P Andreadis","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e000475","DOI":"10.1136\/bmjdrc-2017-000475","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with retinal\n                    adverse events in the FDA Adverse Event Reporting System","volume":"6","author":"G P Fadini","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: Clue to the\n                    mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"J F Rehfeld","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of\n                    gallbladder and biliary diseases: A systematic review and meta-analysis of\n                    randomized clinical trials","volume":"182","author":"L He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating\n                    obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A\n                    narrative review","volume":"39","author":"M K Mahapatra","year":"2022","journal-title":"Pharm Res"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2550-6470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:35:42Z","timestamp":1762299342000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2550-6470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":47,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2550-6470","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}